Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.04.2013 | original article | Ausgabe 7-8/2013

Wiener klinische Wochenschrift 7-8/2013

Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis

Zeitschrift:
Wiener klinische Wochenschrift > Ausgabe 7-8/2013
Autoren:
MD Sonja Burgstaller, Michael Fridrik, Sabine Hojas, Thomas Kühr, Heinz Ludwig, Beate Mayrbäurl, Rainer Pöhnl, Michael Pötscher, Ernst Schlögl, Daniela Zauner, Josef Thaler, Heinz Gisslinger

Summary

Current literature provides conflicting evidence regarding the efficacy of lenalidomide in patients with myelofibrosis (MF). The aim of this work was to evaluate the efficacy of lenalidomide in patients with MF treated within a named patient program in Austria. A total of 22 patients with MF were treated with lenalidomide in 7 different centres throughout Austria. Median age of patients was 68 years. Primary MF was present in 13 patients. Eight patients had post-polycythemia vera (post-PV) and 1 post-essential thrombocythemia (post-ET) MF. According to the Dynamic International Prognostic Scoring System (DIPSS), all patients were scored within the intermediate-2 or high-risk group. Approximately one-third of patients were treated with 2 or more prior therapies. The overall response rate according to International Working Group (IWG) criteria was 12.5 %. Efficacy of lenalidomide was moderate in this non-study patient population. Limiting factors seemed to be stage of disease and risk profile of patients included in this analysis.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 7-8/2013

Wiener klinische Wochenschrift 7-8/2013Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

Jahreshauptversammlung 2013